Evidence map›Paper›PMID 38605020›Full record

ArticleNPJ breast cancer2024

Genomic spectrum of actionable alterations in serial cell free DNA (cfDNA) analysis of patients with metastatic breast cancer.

Yael Bar, Jennifer C Keenan, Andrzej Niemierko, Arielle J Medford, Steven J Isakoff, Leif W Ellisen, Aditya Bardia, Neelima Vidula

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ breast cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Targeting tumor transition windows.Exploration of targeted anti-tumor therapy · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Yael BarMassachusetts General Hospital Cancer Center, Boston, MA, USA. yael.b@tlvmc.gov.il.ORCID http://orcid.org/0000-0002-5762-5621
Jennifer C KeenanMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Andrzej NiemierkoMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Arielle J MedfordMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Steven J IsakoffMassachusetts General Hospital Cancer Center, Boston, MA, USA.ORCID http://orcid.org/0000-0002-6677-1014
Leif W EllisenMassachusetts General Hospital Cancer Center, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0444-7910
Aditya BardiaMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Neelima VidulaMassachusetts General Hospital Cancer Center, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5963-7052
Harvard University · USMassachusetts General Hospital · USTel Aviv Sourasky Medical Center · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We aimed to study the incidence and genomic spectrum of actionable alterations (AA) detected in serial cfDNA collections from patients with metastatic breast cancer (MBC). Patients with MBC who underwent plasma-based cfDNA testing (Guardant360

Identifiers

PMID38605020
PMCPMC11009384
OpenAlexW4394712192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.